Grown Rogue International (GRUSF) Non-Current Debt (2009 - 2026)
Grown Rogue International's (GRUSF) quarterly Non-Current Debt came in at $9.9 million in Q1 2026, up 46.69% year-on-year from $6.8 million in Q1 2025, and down 1.03% quarter-over-quarter from $10.0 million in Q4 2025.
Grown Rogue International (GRUSF) Non-Current Debt (2009 - 2026) Analysis & Trends
Grown Rogue International's Non-Current Debt history runs 17 years deep, the most recent figure standing at $9.9 million for Q1 2026.
- On a quarterly basis, Non-Current Debt rose 46.69% year-over-year to $9.9 million in Q1 2026; TTM through Mar 2026 was $9.9 million, a 46.69% increase from a year earlier, with the FY2025 full-year figure at $10.0 million, up 383.07% from the prior year.
- Non-Current Debt declined to $9.9 million in Q1 2026 per GRUSF's latest filing, from $10.0 million in the prior quarter.
- Across five years, Non-Current Debt topped out at $10424.6 billion in Q3 2025 and bottomed at $60486.1 in Q4 2023.
- The 5-year median for Non-Current Debt is $1.5 million (2024), against an average of $744.6 billion.
- Across the five-year window, Non-Current Debt slumped 87.74% in 2023 and jumped 922180181.77% in 2025, its largest moves.
- Year by year, Non-Current Debt stood at $839222.0 in 2022, then tumbled by 92.79% to $60486.1 in 2023, then soared by 3329.07% to $2.1 million in 2024, then soared by 383.07% to $10.0 million in 2025, then decreased by 1.03% to $9.9 million in 2026.
- Per Business Quant, the three latest GRUSF Non-Current Debt figures stand at $9.9 million (Q1 2026), $10.0 million (Q4 2025), and $10424.6 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 10.34 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 14.02 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 9.05 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 27.86 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 12.41 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 3.74 Bn |
| 10 | Grown Rogue International | 99.97 Mn | 92.67 Mn | 3.96 Mn | 9.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.92 Mn |
| Dec 31, 2025 | 10.02 Mn |
| Sep 30, 2025 | 10,424.63 Bn |
| Jun 30, 2025 | 6.59 Mn |
| Mar 31, 2025 | 6.76 Mn |
| Dec 31, 2024 | 2.07 Mn |
| Sep 30, 2024 | 1.13 Mn |
| Jun 30, 2024 | 1.18 Mn |
| Mar 31, 2024 | 1.78 Mn |
| Dec 31, 2023 | 60,486.06 |
| Oct 31, 2023 | 102,913.00 |
| Apr 30, 2023 | 289,854.00 |
| Jan 31, 2023 | 339,664.00 |
| Oct 31, 2022 | 839,222.00 |
| Oct 31, 2021 | 1.37 Mn |
| Apr 30, 2021 | 1.17 Mn |
| Jan 31, 2021 | 1.05 Mn |
| Oct 31, 2020 | 753,715.00 |
| Jul 31, 2020 | 485,855.00 |
| Apr 30, 2020 | 585,191.00 |